Advances in the development of retinoids as chemopreventive agents

Area of Science:

• Molecular Biology
• Pharmacology
• Oncology

Background:

• Retinoids are crucial in cell differentiation and proliferation, with established roles in cancer chemoprevention.
• Retinoid signaling is complex, involving six nuclear receptors (RARs and RXRs) with diverse functions and ligand specificities.
• Current retinoid drug development aims to reduce toxicity while maintaining or enhancing anticancer activity.

Purpose of the Study:

• To review recent advances in retinoid molecular targeting for chemoprevention.
• To highlight strategies for developing retinoids with improved safety and efficacy profiles.
• To explore novel mechanisms and combinations for retinoid-based cancer prevention.

Main Methods:

• Review of animal carcinogenesis models (skin, breast, oral, lung, prostate, bladder) and clinical trials (head and neck, cervix).
• Analysis of molecular targets, focusing on retinoic acid receptors (RARs) and retinoid X receptors (RXRs).
• Exploration of newly identified retinoid-regulated genes and receptor-independent mechanisms.

Main Results:

• RXR-selective ligands show reduced toxicity and enhanced activity in breast cancer prevention compared to RAR ligands.
• Development of receptor-selective synthetic retinoids is a key strategy for reducing toxicity.
• Novel approaches include targeting retinoid-regulated genes, exploring receptor-independent apoptosis, and using synergistic combinations.

Conclusions:

• Targeting retinoid receptors, particularly RXRs, offers a promising strategy for developing safer and more effective chemopreventive agents.
• Further research into novel retinoid mechanisms and drug delivery systems can enhance their therapeutic potential.
• Retinoid-based chemoprevention holds significant promise for various cancers, with ongoing molecular advancements.